PCV43 Comparison of Dabigatran Etexilate Versus Warfarin for Stroke Prevention in Atrial Fibrillation in Ireland Over 5 Years  by McCarron, C. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A519
for treatment with dabigatran. It is assumed that all diagnosed AF patients eligible 
for oral anticoagulation currently receive warfarin and that all patients switch to 
dabigatran in Year 1, regardless of International Normalised Ratio (INR) control 
amongst warfarin patients. Differences in numbers of clinical events expected to 
occur based on a patient’s antithrombotic treatment were estimated by applying 
event rates from literature sources. Costs were estimated from a HSE perspective and 
included costs of clinical events, disability costs and medication costs. Results: 
A total of 28,332 Irish patients are estimated to have been diagnosed with AF and 
are eligible for dabigatran. Switching these patients from warfarin to dabigatran 
may avoid: 657 strokes; 792 major bleeds; 1,437 deaths. By Year 5, cumulative dabi-
gatran drug costs were estimated at € 7,670,870. Cost savings due to clinical events 
avoided amounted to € 2,894,743 and savings on disability costs at € 5,563,349, giving 
a total cost saving with dabigatran of € 787,223. ConClusions: Use of dabigatran 
as compared to warfarin for stroke prevention in AF in the Irish setting may avoid 
a significant number of clinical events and result in overall cost savings.
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objeCtives: To conduct a literature review on the economic burden of venous throm-
boembolism (VTE) (encompassing deep vein thrombosis (DVT) and pulmonary embo-
lism (PE)) and related complications. Methods: Eligible English-language studies 
published post-1990 were identified from electronic databases (Medline, EMBASE 
and Cochrane Library: accessed December 2012) and conference proceedings with 
no restriction on geographical location or patient population. All costs are reported 
in US$ adjusted to 2013 levels. Results: Twenty-nine studies met eligibility criteria: 
United States (n= 17), Canada (n= 2), Australia (n= 1), South America (n= 1) and Europe 
(n= 8). The estimated annual cost of VTE treatment is in excess of $2 billion in the 
USA and Europe and $153 million in Australia. This figure rises to $15.6–$34.8 billion 
in the US and to $1.78 billion in Australia on inclusion of complications, productivity 
loss and other societal costs. The cost of treating PE per patient ($12,567-$20,488) is 
higher than that of treating DVT ($2,912-$13,299). Hospitalisation is the main cost 
driver for VTE treatment, accounting for 56%-89% of all treatment costs. For patients 
with cancer, costs were 30-50% higher for those with VTE compared with those with-
out VTE. VTE-related complications incur additional costs including: bleeding (up to 
$23,963 per patient with a major bleed); recurrent VTE (up to $18,122 per patient); 
post-thrombotic syndrome (increase of up to 75% in treatment cost); chronic throm-
boembolic pulmonary hypertension (up to $6,708 per patient); and heparin-induced 
thrombocytopenia (up to $18,779 per patient). ConClusions: Incident VTE events 
and related complications are associated with significant economic burden across 
several patient populations. Treating PE may cost up to five times more than treating 
DVT, with hospitalisation reported as the major cost driver of VTE treatment. Effective 
and convenient therapies associated with both a reduced incidence of bleeding and 
complications are required to further reduce the cost burden associated with VTE.
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objeCtives: To assess the cost-effectiveness of actovegin and solcoseryl in the treat-
ment of Russian patients with acute ischemic stroke and predict potential budget 
impact of the implementation of actovegin in routine clinical practice. Methods: 
The pharmacoeconomic model was developed based on the data from Russian 
clinical trial performed by A. Fedin et al. (2000). Two groups of patients (100 persons 
each) hospitalized with acute ischemic stroke were included in the model. The first 
group of patients received conventional therapy + actovegin and the second group 
received conventional therapy + solcoseryl. Based on the reported by A. Fedin et al. 
time-dependent mortality reduction in actovegin-treated patients (mortality rate 
was 7% in patients started actovegin within the first 6 hours after stroke onset, 
10% – in those started actovegin within the first 24 hours, 14% – in those started 
actovegin after more than 24 hours, and it was much higher in the control group – 
21%) cost-effectiveness ratios (CERs) and indicator of economic rationality of costs 
of previous periods (IRPP) were calculated and compared. Results: Estimated CERs 
varied from 46,348.82 to 50,121.40 RUB per one survivor in the actovegin group and 
from 50,900.56 to 53,585.17 RUB per one survivor in the solcoseryl group. Inefficient 
expenditures (IRPP) varied from 301,730.83 RUB to 603,461.67 RUB in the actovegin 
group, and were 873,453.57 RUB in the solcoseryl group. ConClusions: The study 
has demonstrated the preferred cost-effectiveness profile of actovegin as compared 
to solcoseryl in patients with acute ischemic stroke.
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objeCtives: To assess the cost-effectiveness of citicoline in the treatment of Russian 
patients with acute ischemic stroke and identify potential budget impact of the imple-
mentation of citicoline in routine clinical practice. Methods: The pharmacoeco-
nomic model was developed based on the data of meta-analysis performed by A. 
Davalos et al. (2002). Two groups of 100 patients each were included in the model: the 
first group of patients received conventional therapy and the second group (active 
treatment group) additionally received citicoline. It was assumed that citicoline was 
given to patients in the active treatment group in the following way: during the first 
repeat procedure rates (TLR - target lesion revascularization) over 1 year. The model 
was developed from a Italian national health care system (NHS) perspective with 
a 5-year time horizon. A systematic literature review was carried out on TLR rates 
in patients with femoral-popliteal disease treated with one of the four treatment 
choices. Costs associated to each treatment are derived from the average DRG tariffs 
used for peripheral angioplasty procedures. A decision analytic model was devel-
oped to estimate total costs over 12 months of index procedures and possible revas-
cularizations. Results: Pooled 12-month TLR rates show clear patients benefit with 
DEB compared to PTA (8,6% vs 28,6%) and non-inferiority of DEB vs DES (9,4%) and 
BMS (11,5%). Total Italian DRG payments for index and repeat interventions (based 
on TLR rates estimation) across treatments showed that DEB was the least costly 
treatment strategy over 1 year, with saving of almost € 1,000 per patient with DEB 
vs PTA. Based on these per-patient savings, the potential total savings amounted 
to approximately € 2 million for an assumed annual increase of 5% in DEB adoption 
rate over 5 years. ConClusions: The analysis suggests clear patient benefit for 
DEB. Despite initial higher investments, DEB represents a cost-saving alternative 
to other technologies according to the NHS perspective.
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objeCtives: In Italy about 500,000 non-valvular atrial fibrillation (NVAF) patients 
have a major unmet medical need as they do not receive adequate anticoagulation 
therapy for stroke prophylaxis: many patients receive antiplatelet therapy, even 
when the guidelines recommend vitamin-K antagonists (VKA), or are not treated at 
all or have international normalized ratio inadequate control despite treatment with 
VKA. The purpose of this study was to perform a budget impact analysis of rivaroxa-
ban - a novel oral anticoagulant (NOAC) - in NVAF patients with the highest unmet 
medical need from the Italian health care system (SSN) perspective. Methods: 
Two scenarios were compared within a three-year timeframe: the actual scenario, 
where patients are treated according to current clinical practice (46% with VKA, 
38% with antiplatelets, 17% non-treated) and a scenario where Rivaroxaban is pre-
sent with increasing market shares. The event risks (ischemic and haemorrhagic 
stroke, systemic embolism, myocardial infarction and bleedings) were retrieved 
from the ROCKET-AF trial or from a network meta-analysis. Resource consumption 
was computed using mean regional tariffs. Since Rivaroxaban price is not officially 
published, the daily cost used ranges from € 2.10 (price of the first NOAC approved in 
this indication in Italy) and the lowest Rivaroxaban price available in Europe (€ 1.94). 
The results of the analysis are displayed as a total costs difference between the two 
scenarios. Results: A reduction in the total number of events and costs at SSN 
charge is shown since the first year from rivaroxaban introduction. The increase in 
pharmaceutical expenditure is offset by savings from a lower number of events to 
treat and absence of routine coagulation monitoring. ConClusions: The introduc-
tion of rivaroxaban in the national scenario is beneficial because it will provide a 
substantial reduction in the disease burden for patients and in costs for the SSN.
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objeCtives: To estimate the number of clinical events and costs of these events 
for dabigatran etexilate (dabigatran) versus a combination of warfarin, aspirin and 
no treatment for stroke prevention in atrial fibrillation (AF) patients in an England, 
UK, setting over 5 years. Methods: An interactive model was built in Microsoft 
Excel to calculate the following: • Total number of AF patients eligible for dabi-
gatran • Number of clinical events for dabigatran, warfarin, aspirin and no treat-
ment patients over a 5 year time horizon. Clinical events included were stroke 
(ischaemic, haemorrhagic, systemic embolism); major bleeding (intracranial and 
extracranial); all cause mortality; acute myocardial infarction • Total costs of clini-
cal events for each treatment. The total cost per day for dabigatran is £2.20 per day; 
warfarin is £1.18; aspirin is £0.09; no treatment is £0.00. Warfarin had a TTR of 55% 
(from Jones et al 2005); aspirin and no treatment clinical event rates were from 
Roskell et al (2010). Dabigatran data was from the RE-LY trial Results: The model 
estimates there are 822,527 patients with AF in England, of which 78% are eligible 
for dabigatran (641,571). After 5 years, patients treated with dabigatran versus 80% 
with warfarin; 10% aspirin; 10% no treatment are associated with: 1) 27,357 fewer 
strokes (16,938 fewer ischaemic storkes); 2) 14,413 fewer major bleeding events; 
and 3) An increase of £268,167,861 in drug budget; however there is an overall cost 
saving of £11,240,201. The overall cost saving is predominantly driven by savings in 
disability following stroke. ConClusions: Study indicates that due to a superior 
clinical profile, dabigatran may more than offset the increase drug budgets, result-
ing in cost savings, if used preferentially versus warfarin, aspirin or no treatment.
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objeCtives: To estimate numbers of clinical events (strokes, major bleeds, acute 
myocardial infarctions and deaths) and health care costs over a five year period 
in Ireland following a switch of antithrombotic therapy for atrial fibrillation (AF) 
from warfarin to dabigatran. Methods: A model was built in Microsoft Excel and 
included an estimate of the number of Irish patients diagnosed with AF and eligible 
